Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial.
Levine A, Kori M, Kierkus J, Sigall Boneh R, Sladek M, Escher JC, Wine E, Yerushalmi B, Amil Dias J, Shaoul R, Veereman Wauters G, Boaz M, Abitbol G, Bousvaros A, Turner D. Levine A, et al. Among authors: veereman wauters g. Gut. 2019 Feb;68(2):239-247. doi: 10.1136/gutjnl-2017-315199. Epub 2018 Feb 2. Gut. 2019. PMID: 29420227 Clinical Trial.
Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study.
Levine A, Turner D, Pfeffer Gik T, Amil Dias J, Veres G, Shaoul R, Staiano A, Escher J, Kolho KL, Paerregaard A, Martin de Carpi J, Veereman Wauters G, Koletzko S, Shevah O, Finnby L, Sladek M. Levine A, et al. Among authors: veereman wauters g. Inflamm Bowel Dis. 2014 Feb;20(2):278-85. doi: 10.1097/01.MIB.0000437735.11953.68. Inflamm Bowel Dis. 2014. PMID: 24390062
ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents.
Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL, Veres G, Russell RK, Paerregaard A, Buderus S, Greer ML, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC; European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Levine A, et al. Among authors: veereman wauters g. J Pediatr Gastroenterol Nutr. 2014 Jun;58(6):795-806. doi: 10.1097/MPG.0000000000000239. J Pediatr Gastroenterol Nutr. 2014. PMID: 24231644
Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, Kugathasan S, Cohen S, Markowitz J, Escher JC, Veereman-Wauters G, Crandall W, Baldassano R, Griffiths A; T72 Study Group. Hyams J, et al. Among authors: veereman wauters g. Clin Gastroenterol Hepatol. 2012 Apr;10(4):391-9.e1. doi: 10.1016/j.cgh.2011.11.026. Epub 2011 Dec 8. Clin Gastroenterol Hepatol. 2012. PMID: 22155755 Clinical Trial.
Rapid test for fecal calprotectin levels in children with Crohn disease.
Kolho KL, Turner D, Veereman-Wauters G, Sladek M, de Ridder L, Shaoul R, Paerregaard A, Amil Dias J, Koletzko S, Nuti F, Bujanover Y, Staiano A, Bochenek K, Finnby L, Levine A, Veres G. Kolho KL, et al. Among authors: veereman wauters g. J Pediatr Gastroenterol Nutr. 2012 Oct;55(4):436-9. doi: 10.1097/MPG.0b013e318253cff1. J Pediatr Gastroenterol Nutr. 2012. PMID: 22411269
Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group.
de Ridder L, Turner D, Wilson DC, Koletzko S, Martin-de-Carpi J, Fagerberg UL, Spray C, Sladek M, Shaoul R, Roma-Giannikou E, Bronsky J, Serban DE, Cucchiara S, Veres G, Ruemmele FM, Hojsak I, Kolho KL, Davies IH, Aloi M, Lionetti P, Veereman-Wauters G, Braegger CP, Trindade E, Wewer AV, Hauer A, Levine A; Porto IBD Working Group of ESPGHAN. de Ridder L, et al. Among authors: veereman wauters g. Inflamm Bowel Dis. 2014 Feb;20(2):291-300. doi: 10.1097/01.MIB.0000439066.69340.3c. Inflamm Bowel Dis. 2014. PMID: 24374875 Free article.
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN; Reach Study Group. Thayu M, et al. Among authors: veereman wauters g. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1378-84. doi: 10.1016/j.cgh.2008.07.010. Clin Gastroenterol Hepatol. 2008. PMID: 19081527 Clinical Trial.
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group. Hyams J, et al. Among authors: veereman wauters g. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. Epub 2006 Dec 3. Gastroenterology. 2007. PMID: 17324398 Clinical Trial.
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension.
Hyams J, Walters TD, Crandall W, Kugathasan S, Griffiths A, Blank M, Johanns J, Lang Y, Markowitz J, Cohen S, Winter HS, Veereman-Wauters G, Ferry G, Baldassano R. Hyams J, et al. Among authors: veereman wauters g. Curr Med Res Opin. 2011 Mar;27(3):651-62. doi: 10.1185/03007995.2010.547575. Epub 2011 Jan 18. Curr Med Res Opin. 2011. PMID: 21241207 Clinical Trial.
61 results